Navigation Links
NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference
Date:11/23/2009

SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, Chairman and Chief Executive Officer, and Michael J. Lambert, Executive Vice President and Chief Financial Officer, are scheduled to present at the 21st Annual Piper Jaffray Health Care Conference at the New York Palace in New York, New York, on Wednesday, December 2, 2009, at 10:00 a.m. ET. Mr. Lukianov and Mr. Lambert are also scheduled to present at the J.P. Morgan SMid Cap Conference at the J.P. Morgan Conference Center at 383 Madison Avenue in New York, New York, on Thursday, December 3, 2009, at 1:30 p.m. ET.

A live webcast of both presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentations will remain available on the website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision®, a proprietary software-driven nerve avoidance system; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With nearly 50 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


Contact:                           Investors:
Michael Lambert                    Patrick F. Williams
EVP & Chief Financial Officer      Vice President, Finance &
NuVasive, Inc.                      Investor Relations
858-909-1998                       NuVasive, Inc.
investorrelations@nuvasive.com     858-638-5511
                                   investorrelations@nuvasive.com

Media:
Jason Rando
The Ruth Group
646-536-7025
jrando@theruthgroup.com

SOURCE NuVasive, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NuVasive to Present at the JMP Securities Healthcare Focus Conference
2. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
3. NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference
4. NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) ... Gavras , M.D., following today,s Institute for Clinical and Economic ... on the effectiveness and value of abuse-deterrent formulations (ADF) ... the policy roundtable at the meeting. ... a material cost benefit to the use of abuse-deterrent formulations ...
(Date:7/14/2017)... -- Endo International plc (NASDAQ: ENDP ) will announce ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 45397076. Please dial in 10 minutes prior to ... A replay of the call will be available from August 8, ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Summers in Palm Springs sizzle, but ... — think homemade gourmet ice cream, sparkling pools, and mile-high fun. , At Arrive's ... mugs, journals, and other must-have knick knacks. Ice cream and sorbet flavors rotate, but ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Donna ... University recently co-authored and published an article in the medical science journal Physical ... Palsy. Both the article and the research that helped produce it, were written ...
(Date:7/25/2017)... Austin, TX (PRWEB) , ... July 25, 2017 , ... ... medical emergencies in the Austin, TX area 24 Hours a day. , The ... in Austin, TX. , “We’ve been open four months now and things are ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cosmetic Town, an online plastic surgery ... surgeries they perform on a daily basis. , The new video series will ... specialize in at their practices. , When asked about the new video series, ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will ... essential tremor (ET). The seminar will take place on Saturday, Aug. 26 at the ... The program will run from 9 a.m. to 12 p.m., with check-in beginning at ...
Breaking Medicine News(10 mins):